AFT painkiller Maxigesic now licensed in Mexico

Market release
27 December 2017

AFT Pharmaceuticals’ painkiller Maxigesic now licensed in first North American market,
Mexico, taking licensed countries to 125.

AFT Pharmaceuticals (‘AFT’) has extended its existing agreements to add the Mexican
company, Laboratories Expanscience Mexico SA (‘Expanscience Mexico’) to out-license
the product line of its patented combination painkiller,
Maxigesic, to Mexico.

Expanscience Mexico is a wholly owned subsidiary of privately-owned French
pharmaceutical company, Laboratoires Expanscience S.A. (‘Expanscience’) which already
holds
Maxigesic rights for France.

Maxigesic consists of a patented, fixed ratio of ibuprofen for anti-inflammation
management and paracetamol (also called acetaminophen) for pain management.
Maxigesic products covered by the new licensing agreement include tablet, oral liquid,
fast-dissolve and dry powder sachets.

AFT Managing Director, Dr Hartley Atkinson, says that he is very pleased to further
extend the company’s partnership with Expanscience.

“We had previously disclosed our target to sell
Maxigesic to 100 countries in the
disclosure statement. As a result of this latest partnership with Expanscience, we have
now further increased our agreements to some 125 countries. Importantly we’ve now
added our first market in North America. Mexico is the fifteenth largest market in the
world for sales of Paracetamol tablets and of Ibuprofen oral tablets.”

“Although we will need to complete product registrations in Mexico in the near future,
we anticipate sales to commence within the FY19 time period. As previously noted, we
have experienced some delays in launches due to regulatory delays in various countries,
but the number of
Maxigesic launches to occur within the FY19 time period is increasing
with over 30 new launches anticipated.”

We believe that Mexico represents good potential for
Maxigesic as the market defined
by
IMS Health for paracetamol tablet and ibuprofen tablet sales in Mexico is close to an
aggregate of US$200M.”

Ferghana Partners (New York, London, Boston) initiated these transactions and provided
strategic/financial advisory services to AFT Pharma.

About Expanscience Mexico SA
Laboratorios Expanscience Mexico, S.A. DE C.V., a company incorporated in Mexico and
having its registered office at Blvd Miguel Cervantes de Saavedra 233, Colonia Grenada,
C.P. 11520 México and wholly owned subsidiary of Laboratoires Expanscience is a
pharmaceutical company incorporated in France having its registered office at 1 Place
des Saisons 92048 Paris La Defense Cedex, Paris, France

End of release
For more information:
Hartley Atkinson
Managing Director, AFT Pharmaceuticals Ltd
Phone +64 9 488 0232